儿童呼吸道感染的RSV检测和抗生素处方决定
Riccardo Boracchini1,2, Giulia Brigadoi3, Sara Salvadori1
1Laboratory of Healthcare Research and Pharmacoepidemiology, Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
JAMA network open
|March 3, 2026
概括
快速抗原诊断测试 (Ag-RDTs) 呼吸道同胞病毒 (RSV) 显著减少了对儿科下呼吸道感染 (LRTI) 的抗生素处方. 这种抗微生物管理工具在支气管炎病例中显示出特别的益处.
科学领域:
- 儿童传染病 儿童传染病
- 抗微生物药物管理管理
- 诊断测试使用率的测试.
背景情况:
- 呼吸道同胞性病毒 (RSV) 是儿科病毒性下呼吸道感染 (VLRTI) 的主要原因,经常导致不必要的抗生素处方.
- 快速抗原诊断测试 (Ag-RDTs) 对社区儿科对VLRTI的抗生素处方的影响尚不清楚.
研究的目的:
- 评估RSV Ag-RDTs的实施与LRTIs诊断的婴儿和儿童的抗生素处方模式之间的关联.
- 评估RSV Ag-RDTs作为门诊儿科护理中抗菌药物管理的工具.
主要方法:
- 一项回顾性队列研究分析了2023年12月至2024年5月间意大利家庭儿科医生 (Pedianet网络) 的数据.
- 患有VLRTI症状的9-36个月龄的儿童接受了RSV Ag-RDT,并与历史和当代未经测试的队列进行了比较.
- 诊断后14天内处方抗生素 (不包括细菌感染) 是主要结局,使用日志-二项式回归分析.
主要成果:
- 与未经测试的队列相比,RSV Ag-RDT的实施与对VLRTI (RR 0.54-0.61) 和支气管炎 (RR 0.56) 的抗生素处方显著减少有关.
- 与RSV阴性儿童相比,RSV阳性儿童接受的抗生素较少 (RR0.52).
- 抗生素使用的减少在RSV阳性病例中更为明显,特别是VLRTI (RR 0.33-0.41) 和支气管炎 (RR 0.33).
结论:
- RSV Ag-RDTs作为有效的门诊抗菌药物管理工具,特别用于儿童支气管炎的管理.
- 广泛采用RSV Ag-RDTs,以及免疫预防,可以提高诊断准确性,并可能改善临床结果.
- 研究结果表明,RSV是儿童群体中广泛的VLRTI的重要贡献者.
相关概念视频
Acute Pharyngitis
6.6K
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
6.6K
Pneumonia III: Complications and Assessment
1.4K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K
Pneumonia IV: Management
1.2K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K
Acute Respiratory Failure-V
775
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
775
Pharmacokinetics in Pediatric Patients: Drug Excretion
414
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
414
Mechanism of Antibiotic Resistance in MRSA
251
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
251


